Chugai Pharmaceutical (OTCMKTS:CHGCY) Sees Strong Trading Volume – What’s Next?

Shares of Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) saw unusually-strong trading volume on Thursday . 495,485 shares traded hands during mid-day trading, an increase of 111% from the previous session’s volume of 234,746 shares.The stock last traded at $23.43 and had previously closed at $23.66.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on CHGCY shares. Smbc Nikko Sec. upgraded Chugai Pharmaceutical to a “strong-buy” rating in a report on Wednesday, February 25th. Zacks Research raised shares of Chugai Pharmaceutical to a “hold” rating in a research report on Friday, May 29th. Finally, The Goldman Sachs Group upgraded shares of Chugai Pharmaceutical from a “hold” rating to a “buy” rating in a report on Monday. Two investment analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Buy”.

Chugai Pharmaceutical Stock Performance

The firm’s 50 day simple moving average is $25.32 and its 200 day simple moving average is $27.10. The firm has a market capitalization of $77.13 billion, a price-to-earnings ratio of 26.04 and a beta of 0.58.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last issued its earnings results on Friday, April 24th. The company reported $0.22 EPS for the quarter. The firm had revenue of $2.05 billion for the quarter. Chugai Pharmaceutical had a return on equity of 22.90% and a net margin of 34.98%. As a group, sell-side analysts forecast that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.98 earnings per share for the current year.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co, Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. The company develops both biologics and small-molecule therapies, with particular emphasis on oncology and immunology as well as treatments for bone and metabolic disorders. Chugai’s activities span the full drug lifecycle from early research and clinical development through regulatory approval, manufacturing and post-marketing support.

Chugai is known for its research-driven approach and its work on monoclonal antibodies and other biologic therapeutics.